Welcome to our dedicated page for Aldeyra Therapeu SEC filings (Ticker: ALDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aldeyra Therapeutics' SEC filings reveal the detailed progress of a clinical-stage biotechnology company advancing novel therapies through complex regulatory pathways. The company's 10-K annual reports and 10-Q quarterly filings provide comprehensive disclosures about clinical trial designs, patient enrollment status, regulatory interactions, and cash runway—critical information for assessing a pre-revenue biotech company's prospects.
For Aldeyra, the most valuable filing insights include detailed descriptions of ongoing clinical trials across multiple indications, explanations of regulatory pathways like orphan drug and fast track designations, and disclosures about manufacturing partnerships for drug supply. The company's filings explain complex clinical endpoints used in ophthalmology trials, helping investors understand what success looks like in conditions like noninfectious anterior uveitis and dry eye disease. Quarterly reports track patient enrollment rates and trial timelines, providing visibility into development progress between major announcements.
Form 4 insider transaction filings show when Aldeyra executives and directors buy or sell shares, potentially signaling management's confidence during critical development stages. 8-K filings announce material events such as clinical trial results, FDA communications, and strategic partnerships—often containing the most market-moving information. Proxy statements (DEF 14A) detail executive compensation structures, including stock-based incentives tied to clinical and regulatory milestones, revealing what achievements the board prioritizes.
Our AI-powered summaries extract key data from these technical documents, highlighting changes in cash positions, updates to clinical trial timelines, new risk factor disclosures, and explanations of regulatory feedback. No need to decode hundreds of pages of pharmaceutical development terminology—get the insights that matter for tracking this ophthalmology-focused biotech's path toward potential product approvals.
Aldeyra Therapeutics, Inc. reported that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) date for topical ocular reproxalap, an investigational drug candidate for the treatment of signs and symptoms of dry eye disease. The update relates to the ongoing review of the new drug application for reproxalap.
The company issued a press release on
Aldeyra Therapeutics (ALDX) announced an R&D webcast and materials. On November 13, 2025, the company is presenting a slide deck at its 2025 Research & Development Webcast, furnished as Exhibit 99.1.
In a related press release filed as Exhibit 99.2, Aldeyra highlights two updates: expansion of its RASP platform to include central nervous system diseases, and manufacturing updates on reproxalap, its first-in-class investigational candidate for the signs and symptoms of dry eye disease.
The company notes forward-looking statements regarding development timelines, regulatory outcomes, and commercialization are subject to risks and uncertainties. Information furnished under Item 7.01 is not deemed “filed” or subject to Section 18 of the Exchange Act.
Aldeyra Therapeutics reported Q3 2025 results with a net loss of
Liquidity and balance sheet: Cash and cash equivalents were
Strategic items: Deferred collaboration revenue remained
Aldeyra Therapeutics (ALDX) furnished an 8-K noting it issued a press release announcing positive Phase 2 results in alcohol-associated hepatitis, the prioritization of its RASP modulator product candidates, and an updated pipeline.
The company also reported an extension of its projected operational cash runway into the second half of 2027. The press release is included as Exhibit 99.1.
Aldeyra Therapeutics officer and director Michael Alfieri reported a non-derivative purchase of 2,500 shares of Aldeyra common stock on 08/13/2025 at a reported price of $5.30 per share. Following the transaction he beneficially owns 2,500 shares directly. The Form 4 was signed on 08/15/2025.
Perceptive Advisors and affiliated parties report a 6.8% stake in Aldeyra Therapeutics (ALDX), representing 4,051,631 shares. The filing states the Master Fund directly holds the shares, with Perceptive Advisors as investment manager and Joseph Edelman as managing member, each deemed to beneficially own the shares. All reported shares reflect shared voting and dispositive power (no sole power). The ownership percentage is calculated using 59,895,588 outstanding shares of common stock as reported by the issuer. The filers certify the holdings were not acquired to influence control.
Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics (ALDX), reported the sale of 22,073 shares of common stock on 08/11/2025. The disposals were executed to cover tax withholding obligations upon settlement of time-based restricted stock units. The sales produced a weighted average price of $5.1517, with individual trade prices in the range of $5.06 to $5.29. After the reported transactions the reporting person beneficially owned 221,799 shares, which includes 7,101 shares acquired under the company’s Employee Stock Purchase Plan. No derivative securities were reported.
Aldeyra Therapeutics (ALDX) Form 144 reports a proposed sale of 22,074 shares of common stock through Morgan Stanley Smith Barney on Nasdaq, with an aggregate market value of $116,109.24 and an approximate sale date of 08/12/2025. The filing states the shares were acquired as a Restricted Stock Unit grant on 07/15/2022 (46,401 units acquired) and that the consideration for the original acquisition was services rendered. The filer reports nothing to report for securities sold in the past three months.
The notice includes the seller's representation that they are not aware of any undisclosed material adverse information regarding the issuer.
Aldeyra Therapeutics (ALDX) Q2-25 10-Q shows the clinical-stage biotech remains pre-revenue but reduced operating losses.
- Net loss narrowed to $9.8 m (-42% YoY) on R&D cut to $8.5 m (-43%) and G&A cut to $1.7 m (-45%). Six-month loss fell to $19.7 m (-21%).
- Cash resources: $41.2 m cash & cash equivalents plus $40.7 m marketable securities = $81.9 m, funding “at least the next 12 months.” Cash burn H1-25 was $21.0 m vs $23.2 m prior year.
- Balance sheet shifts: Current liabilities rose to $29.5 m driven by term-loan re-classification (current portion $15.1 m) after interest-only period was extended to Apr-26; long-term debt now zero.
- AbbVie option: $6 m non-refundable fees remain deferred; AbbVie has not exercised the option to co-develop reproxalap and window now only 10 business days post-FDA decision.
- No commercial revenue; accumulated deficit reached $469.8 m.
Management believes existing liquidity plus interest income ($1.9 m YTD) cover operations for 12 months but acknowledges need for additional financing to advance late-stage assets reproxalap (dry eye) and ADX-2191 (retinitis pigmentosa) and to repay the $15.3 m Hercules facility at maturity in 2026.
FAQ
What is the current stock price of Aldeyra Therapeu (ALDX)?
What is the market cap of Aldeyra Therapeu (ALDX)?
